Cadrenal Therapeutics, Inc.宣布其候选药物CAD-1005在二期临床试验中取得积极数据。结果显示,该药物能显著降低血栓事件发生率,为后续临床开发提供有力支持。
Cadrenal Therapeutics, Inc.宣布其候选药物CAD-1005在二期临床试验中取得积极数据。结果显示,该药物能显著降低血栓事件发生率,为后续临床开发提供有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.